{"id":2708,"date":"2019-12-01T12:05:00","date_gmt":"2019-12-01T11:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/therapie-des-akuten-koronarsyndroms-prasugrel-besser-als-ticagrelor-in-der-isar-react-5-studie"},"modified":"2022-03-17T14:14:02","modified_gmt":"2022-03-17T13:14:02","slug":"therapie-des-akuten-koronarsyndroms-prasugrel-besser-als-ticagrelor-in-der-isar-react-5-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/therapie-des-akuten-koronarsyndroms-prasugrel-besser-als-ticagrelor-in-der-isar-react-5-studie","title":{"rendered":"Therapie des Akuten Koronarsyndroms: Prasugrel besser als Ticagrelor in der ISAR-REACT-5-Studie"},"content":{"rendered":"<p>Die antithrombotische Pharmakotherapie ist neben der perkutanen Koronarintervention (PCI) einer der beiden Grundpfeiler in der Behandlung des Akuten Koronarsyndroms (ACS). Sie besteht in der Akutphase aus einem Heparin und einer dualen Antipl\u00e4ttchentherapie (DAPT) mit Azetylsalizyls\u00e4ure (ASS) plus einem P2Y12-Inhibitor; diese DAPT wird f\u00fcr zw\u00f6lf Monate fortgef\u00fchrt. In den vergangenen Jahren haben Ticagrelor und Prasugrel den [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die antithrombotische Pharmakotherapie ist neben der perkutanen Koronarintervention (PCI) einer der beiden Grundpfeiler in der Behandlung des Akuten Koronarsyndroms (ACS). Sie besteht in der Akutphase aus einem Heparin und einer dualen Antipl\u00e4ttchentherapie (DAPT) mit Azetylsalizyls\u00e4ure (ASS) plus einem P2Y12-Inhibitor; diese DAPT wird f\u00fcr zw\u00f6lf Monate fortgef\u00fchrt. In den vergangenen Jahren haben Ticagrelor und Prasugrel den [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,71,5325,85,86,65,83,84,87,1033,79,727,2005],"class_list":["post-2708","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-herzinfarkt","tag-isar-react-5-studie","tag-koronarangiografie","tag-koronarangiographie","tag-myokardinfarkt","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-prasugrel","tag-ptca","tag-thrombozytenaggregationshemmer","tag-ticagrelor"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2708"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2708\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}